Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2023
Date of Report: May 15, 2023
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
This filing serves to incorporate by reference a press release dated May 15, 2023 (Exhibit 99.1) into the company's registration statement on Form F-3. The filing itself contains no narrative business description or operational details beyond the incorporation of the referenced exhibit.
Key Financial Metrics
The provided filing text does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue: Not provided.
- Profit/Loss: Not provided.
- Cash Flow: Not provided.
- Margins: Not provided.
- Debt and Liquidity: Not provided.
Material Changes
The filing text does not provide comparative financial data or narrative descriptions of material changes versus prior periods. Any material changes would be detailed in the incorporated press release (Exhibit 99.1), the content of which is not included in the source text.
Guidance, Outlook, and Risks
Guidance and Outlook: The filing text does not contain management commentary, forward-looking statements, or financial guidance.
Risks and Contingencies: No specific risks or contingencies are disclosed in the body of this Form 6-K.
Unusual Items: No unusual items are described in the provided text.
Investor Verification Checklist
- Verify the content of Exhibit 99.1 (Press Release dated May 15, 2023) to understand the specific event or announcement triggering this filing.
- Review the company's most recent Form 20-F or quarterly reports for actual financial performance data, as this Form 6-K contains no numbers.
- Confirm the status of the registration statement on Form F-3 (File No. 333-252074) referenced for incorporation by reference.